(NASDAQ: OCS) Oculis Holding Ag's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Oculis Holding Ag's earnings in 2026 is -$97,525,862.On average, 11 Wall Street analysts forecast OCS's earnings for 2026 to be -$106,748,099, with the lowest OCS earnings forecast at -$109,852,782, and the highest OCS earnings forecast at -$101,292,825. On average, 10 Wall Street analysts forecast OCS's earnings for 2027 to be -$122,719,892, with the lowest OCS earnings forecast at -$160,451,639, and the highest OCS earnings forecast at -$94,872,857.
In 2028, OCS is forecast to generate -$115,505,071 in earnings, with the lowest earnings forecast at -$151,796,572 and the highest earnings forecast at -$72,046,305.